welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
Healthcare Providers

Kathryn Selby, BSc, MBChB, MRCP, FRCPC

Healthcare Provider
Investigator
BC Children's Hospital
4480 Oak Street
Vancouver, Canada

Dr. Kathryn Selby is an investigator at BC Children’s Hospital. BC Children’s Hospital Research Institute conducts discovery, translational and clinical research to benefit the health of children and their families. Her main area of interest is neuromuscular disorders, with a particular focus on Duchenne muscular dystrophy (DMD). She is also a Clinical Assistant Professor at Department of Pediatrics, University of British Columbia.

Dr. Selby is involved in the development of a Canadian Registry of children with DMD and with congenital myotonic dystrophy and in clinical trials for new potential treatments. Dr. Selby also established a protocol for a natural history study of affected young adults to provide the most appropriate management and care to them.

Her research areas are focused on new treatments in DMD, long-term steroids in DMD, development of a DMD registry in Canada, use of idebenone in Friedreich’s Ataxia, ketogenic diet development, chronic headaches and migraine and metanalysis of cortical venous sinus thrombosis.

 

Representative Publications:

A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy

A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy

Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial

The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study

rareRelated